Pascal Charef

Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate‐to‐severe psoriasis through 5 years of treatment (<scp>SCULPTURE</scp> Extension Study)

Robert Bissonnette, Thomas A. Luger, Diamant Thaçi et al. · Journal of the European Academy of Dermatology and Venereology · 2018 · 193 citations · Full text

Medicine, Dermatology, Pharmacotherapy +16

Randomized, prospective, placebo‐controlled trial of bosentan in interstitial lung disease secondary to systemic sclerosis

James R. Seibold, Christopher P. Denton, Daniel E. Furst et al. · Arthritis & Rheumatism · 2010 · 144 citations

Medicine, Pharmacology, Pharmacotherapy +12

Submaximal exercise testing in the assessment of interstitial lung disease secondary to systemic sclerosis: reproducibility and correlations of the 6-min walk test

Maya H Buch, CP Denton, Daniel E. Fürst et al. · Annals of the Rheumatic Diseases · 2006 · 97 citations · Full text

Medicine, Internal Medicine, Physiology +12

Secukinumab demonstrates high efficacy and a favourable safety profile in paediatric patients with severe chronic plaque psoriasis: 52‐week results from a Phase 3 double‐blind randomized, controlled trial

Christine Bodemer, Andrzej Kaszuba, Külli Kingo et al. · Journal of the European Academy of Dermatology and Venereology · 2020 · 94 citations · Full text

Medicine, Dermatology, Pharmacotherapy +13

Multicenter, Double-Blind, Randomized, Phase 2 Study Evaluating the Novel Antibiotic Cadazolid in Patients with Clostridium difficile Infection

Thomas Louie, Carl Erik Nord, George H. Talbot et al. · Antimicrobial Agents and Chemotherapy · 2015 · 73 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13